News Press Releases

Covalon Announces Attendance at the WOCN® Society & CAET Joint Conference in Montreal

V.COV | June 3, 2016

Covalon Announces Attendance at the WOCN^® Society & CAET Joint Conference in Montreal

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced that it will be exhibiting at this year’s Wound, Ostomy and Continence Nurses Society (WOCN®) and the Canadian Association for Enterostomal Therapy (CAET) joint annual conference taking place on June 4-8, 2016 in Montreal, Canada.

The WOCN^® Society is recognized world-wide for the promotion of safe and effective wound, ostomy and continence (WOC) care. Leading health care organizations recognize the WOCN Society as the premiere nursing specialty organization for educating clinicians to improve WOC patient outcomes.

The CAET is a not-for-profit association specializing in the nursing care of patients with challenges in wound, ostomy and continence. The CAET works to promote high standards for Enterostomal Therapy nursing practice, education, research, and administration to achieve quality specialized nursing care.

“As a Canadian medical technology company with advanced wound and urological products, many of which are manufactured in the United States of America and are used by patients in all corners of the globe, we are very excited to be an exhibitor at this year’s truly international joint conference in Montreal” said John R. Hands, Executive Vice President at Covalon.

Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound and ostomy clinician. Covalon’s CovaWound™ and ColActive® brands, when used together, have the ability to rapidly promote wound closure and healing in both acute and chronic wounds, which remains a major area of focus for health care institutions.

Covalon also markets it’s SilverCoat™ Antimicrobial Silicone Foley Catheter to this audience. SilverCoat™ is a 100% silicone Foley catheter that has a permanent lubricious coating impregnated with silver ions and is intended to help fight bacteria that contribute to Catheter Associated Urinary Tract Infections (CAUTI), one of the most frequent hospital associated infections.

“With the growing awareness of the positive impact that our products have on the lives of patients, we can’t wait to engage the valued members of the WOCN and CAET on why and how their patients can benefit from our products” said Hands.

The WOCN & CAET Joint Conference will be held in the Palais des congrès de Montréal, June 5-7 in Montreal, Canada. Covalon will be exhibiting at Booth 146.

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.